Kim R - Search Results

1

Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma.

Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R. Parikh ND, et al. Among authors: kim r. J Comp Eff Res. 2021 Apr;10(5):343-352. doi: 10.2217/cer-2020-0236. Epub 2021 Jan 14. J Comp Eff Res. 2021. PMID: 33442996 Free article.

2

Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

Eatrides J, Wang E, Kothari N, Kim R. Eatrides J, et al. Among authors: kim r. Cancer Control. 2017 Jul-Sep;24(3):1073274817729243. doi: 10.1177/1073274817729243. Cancer Control. 2017. PMID: 28975834 Free PMC article. Review.

3

A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.

Kim RD, Kovari BP, Martinez M, Xie H, Sahin IH, Mehta R, Strosberg J, Imanirad I, Ghayouri M, Kim YC, Kim DW. Kim RD, et al. Among authors: kim dw, kim yc. Eur J Cancer. 2022 Jul;169:93-102. doi: 10.1016/j.ejca.2022.03.026. Epub 2022 May 5. Eur J Cancer. 2022. PMID: 35526308 Clinical Trial.

4

Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?

Almhanna K, Kim R. Almhanna K, et al. Among authors: kim r. Oncology (Williston Park). 2008 Sep;22(10):1176-83; discussion 1190, 1192, 1196. Oncology (Williston Park). 2008. PMID: 18935928 Free article. Review.

5

Is there a role for second-line chemotherapy in advanced gastric cancer?

Wesolowski R, Lee C, Kim R. Wesolowski R, et al. Among authors: kim r. Lancet Oncol. 2009 Sep;10(9):903-12. doi: 10.1016/S1470-2045(09)70136-6. Lancet Oncol. 2009. PMID: 19717092 Review.

6

What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.

Kim R, Byrne MT, Tan A, Aucejo F. Kim R, et al. Oncology (Williston Park). 2011 Mar;25(3):283-91, 295. Oncology (Williston Park). 2011. PMID: 21548473 Free article. Review.

7

First-line treatment for advanced pancreatic cancer.

Kothari N, Saif MW, Kim R. Kothari N, et al. Among authors: kim r. JOP. 2013 Mar 10;14(2):129-32. doi: 10.6092/1590-8577/1477. JOP. 2013. PMID: 23474553 Free article. Review.

8

Carboplatin and paclitaxel treatment is effective in advanced anal cancer.

Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Kim R, et al. Oncology. 2014;87(2):125-32. doi: 10.1159/000361051. Epub 2014 Jul 8. Oncology. 2014. PMID: 25012155

9

Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.

Sanoff HK, Kim R, Ivanova A, Alistar A, McRee AJ, O'Neil BH. Sanoff HK, et al. Among authors: kim r. Invest New Drugs. 2015 Apr;33(2):505-9. doi: 10.1007/s10637-015-0209-7. Epub 2015 Jan 23. Invest New Drugs. 2015. PMID: 25613083 Free PMC article. Clinical Trial.

10

Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.

Suleiman Y, Mahipal A, Shibata D, Siegel EM, Jump H, Fulp WJ, Springett GM, Kim R. Suleiman Y, et al. Among authors: kim r. Cancer Chemother Pharmacol. 2015 Sep;76(3):481-7. doi: 10.1007/s00280-015-2814-8. Epub 2015 Jul 1. Cancer Chemother Pharmacol. 2015. PMID: 26126727 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,826 results

Search Page

Filters